Condition (MeSH)
Retinitis
ClinicalTrials.gov lists 90 trials for Retinitis or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 22.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
47 of the 90 trials are tagged with Retinitis itself; the rest are tagged with a narrower condition beneath it.
When did Retinitis trials start? (25)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2024 | 1 |
| 2023 | 4 |
| 2022 | 1 |
| 2021 | 3 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 2 |
| 2014 | 1 |
| 2013 | 1 |
Showing 10 of 25 earlier years.
No forecast is made for this condition: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Retinitis trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 10 |
| Phase 1/2 | 1 |
| Phase 2 | 15 |
| Phase 2/3 | 2 |
| Phase 3 | 11 |
| Phase 4 | 3 |
| Not applicable | 27 |
| Observational | 21 |
How many Retinitis trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 4 |
| Active, not recruiting | 3 |
| Completed | 72 |
| Terminated | 1 |
| Withdrawn | 3 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Retinitis trials? (9)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 22 |
| Hoffmann-La Roche | 9 |
| Astra USA | 4 |
| Ionis Pharmaceuticals, Inc. | 4 |
| National Eye Institute (NEI) | 4 |
Showing 5 of 9 sponsors.
Which drugs are being tested for Retinitis? (7)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Ganciclovir | 28 |
| Foscarnet | 13 |
| Cidofovir | 9 |
| Probenecid | 5 |
| Sevirumab | 4 |
Showing 5 of 7 drugs.
Interventions as named in the registry (8)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Valganciclovir | 3 |
| Sagramostim | 2 |
| Gene Therapy Product-MCO-010 | 2 |
| pyrimethamine-sulfadiazine + prednisolone | 1 |
| Sham Procedure | 1 |
Showing 5 of 8 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Retinitis trials report? (9)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Opportunistic Infection | 133 | 1 |
| Neutropenia | 124 | 1 |
| Thrombocytopenia | 37 | 1 |
| Proteinuria 2+ | 24 | 1 |
| Hypokalaemia | 1 | 1 |
Showing 5 of 9 adverse events.
Which publications cover Retinitis? (40)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Exosomes Derived From Mesenchymal Stem Cells Modulate miR-126 to Ameliorate Hyperglycemia-Induced Retinal Inflammation Via Targeting HMGB1. | Investigative ophthalmology & visual science | 2019 | Yes |
| Perfluorocarbon liquid: its application in vitreoretinal surgery and related ocular inflammation. | BioMed research international | 2014 | Yes |
| Non-cytomegalovirus ocular opportunistic infections in patients with acquired immunodeficiency syndrome. | American journal of ophthalmology | 2013 | Yes |
| The effect of mesenchymal stem cells on dynamic changes of T cell subsets in experimental autoimmune uveoretinitis. | Clinical and experimental immunology | 2013 | Yes |
| Mesenchymal stem cells ameliorate experimental autoimmune uveoretinitis by comprehensive modulation of systemic autoimmunity. | Investigative ophthalmology & visual science | 2011 | Yes |
Showing 5 of 40 publications.
Sub-conditions in MeSH (3)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.